Key features and details
- PE/Cy7® Rat monoclonal [A7R34] to CD127
- Suitable for: Flow Cyt
- Reacts with: Mouse
- Conjugation: PE/Cy7®. Ex: 496nm, Em: 774nm
- Isotype: IgG2a
Product namePE/Cy7® Anti-CD127 antibody [A7R34]
See all CD127 primary antibodies
DescriptionPE/Cy7® Rat monoclonal [A7R34] to CD127
ConjugationPE/Cy7®. Ex: 496nm, Em: 774nm
Tested applicationsSuitable for: Flow Cytmore details
Species reactivityReacts with: Mouse
The details of the immunogen for this antibody are not available.
- C57Bl/6 splenocytes.
The A7R34 antibody may be used as a phenotypic marker for IL7R alpha (CD127) on immature B cells, on subsets of thymocytes which are double negative (CD4-CD8-) or single positive (CD4+ or CD8+), and at low levels on mature, peripheral T cells.
This product or portions thereof is manufactured under license from Carnegie Mellon University under U.S. Patent Number 5, 268, 486 and related patents. Cy and CyDye are trademarks of GE Healthcare Limited.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Storage instructionsShipped at 4°C. Store at +4°C. Store In the Dark.
Storage bufferpH: 7.20
Preservative: 0.09% Sodium azide
Constituents: 0.12% Monobasic dihydrogen sodium phosphate, 0.87% Sodium chloride, 0.1% Gelatin
Concentration information loading...
PurityProtein A purified
Purification notesab210242 was purified from tissue culture supernatant via affinity chromatography. The purified antibody was conjugated under optimal conditions, with unreacted dye removed from the preparation.
Light chain typekappa
Our Abpromise guarantee covers the use of ab210242 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Flow Cyt||Use at an assay dependent concentration.
Use 0.5 µg.
FunctionReceptor for interleukin-7. Also acts as a receptor for thymic stromal lymphopoietin (TSLP).
Involvement in diseaseDefects in IL7R are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-positive (T(-)B(+)NK(+) SCID) [MIM:608971]. A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.
Genetic variations in IL7R are a cause of susceptibility to multiple sclerosis type 3 (MS3) [MIM:612595]. A multifactorial, inflammatory, demyelinating disease of the central nervous system. Sclerotic lesions are characterized by perivascular infiltration of monocytes and lymphocytes and appear as indurated areas in pathologic specimens (sclerosis in plaques). The pathological mechanism is regarded as an autoimmune attack of the myelin sheat, mediated by both cellular and humoral immunity. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia and bladder dysfunction. Genetic and environmental factors influence susceptibility to the disease. Note=A polymorphism at position 244 strongly influences susceptibility to multiple sclerosis. Overtransmission of the major 'C' allele coding for Thr-244 is detected in offspring affected with multiple sclerosis. In vitro analysis of transcripts from minigenes containing either 'C' allele (Thr-244) or 'T' allele (Ile-244) shows that the 'C' allele results in an approximately two-fold increase in the skipping of exon 6, leading to increased production of a soluble form of IL7R. Thus, the multiple sclerosis associated 'C' risk allele of IL7R would probably decrease membrane-bound expression of IL7R. As this risk allele is common in the general population, some additional triggers are probably required for the development and progression of MS.
Sequence similaritiesBelongs to the type I cytokine receptor family. Type 4 subfamily.
Contains 1 fibronectin type-III domain.
DomainThe WSXWS motif appears to be necessary for proper protein folding and thereby efficient intracellular transport and cell-surface receptor binding.
The box 1 motif is required for JAK interaction and/or activation.
modificationsN-glycosylated IL-7Ralpha binds IL7 300-fold more tightly than the unglycosylated form.
Cellular localizationSecreted and Cell membrane.
- Information by UniProt
- CD 127 antibody
- CD127 antibody
- CD127 antigen antibody
ab210242 has not yet been referenced specifically in any publications.